Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives

The advancement of immune-therapeutics in cancer treatment has proven to be promising in various malignant diseases. However, in castration resistant prostate cancer (mCRPC) major Phase III trials have been unexpectedly disappointing. To contribute to a broader understanding of the role and use of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Taghizadeh, H., Marhold, M., Tomasich, E., Udovica, S., Merchant, A., Krainer, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791446/
https://www.ncbi.nlm.nih.gov/pubmed/31646092
http://dx.doi.org/10.1080/2162402X.2019.1644109
_version_ 1783458980448698368
author Taghizadeh, H.
Marhold, M.
Tomasich, E.
Udovica, S.
Merchant, A.
Krainer, M.
author_facet Taghizadeh, H.
Marhold, M.
Tomasich, E.
Udovica, S.
Merchant, A.
Krainer, M.
author_sort Taghizadeh, H.
collection PubMed
description The advancement of immune-therapeutics in cancer treatment has proven to be promising in various malignant diseases. However, in castration resistant prostate cancer (mCRPC) major Phase III trials have been unexpectedly disappointing. To contribute to a broader understanding of the role and use of immune-therapeutics in mCRPC, we conducted a systematic review. We searched the websites ClinicalTrials.gov, PubMed and ASCO Meeting Library for clinical trials employing immune checkpoint inhibitors in mCRPC. This article not only describes the rationale of individual trials, but it also summarizes the current status of the field and sheds light on strategies for future success.
format Online
Article
Text
id pubmed-6791446
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-67914462019-10-23 Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives Taghizadeh, H. Marhold, M. Tomasich, E. Udovica, S. Merchant, A. Krainer, M. Oncoimmunology Review The advancement of immune-therapeutics in cancer treatment has proven to be promising in various malignant diseases. However, in castration resistant prostate cancer (mCRPC) major Phase III trials have been unexpectedly disappointing. To contribute to a broader understanding of the role and use of immune-therapeutics in mCRPC, we conducted a systematic review. We searched the websites ClinicalTrials.gov, PubMed and ASCO Meeting Library for clinical trials employing immune checkpoint inhibitors in mCRPC. This article not only describes the rationale of individual trials, but it also summarizes the current status of the field and sheds light on strategies for future success. Taylor & Francis 2019-07-25 /pmc/articles/PMC6791446/ /pubmed/31646092 http://dx.doi.org/10.1080/2162402X.2019.1644109 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Review
Taghizadeh, H.
Marhold, M.
Tomasich, E.
Udovica, S.
Merchant, A.
Krainer, M.
Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
title Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
title_full Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
title_fullStr Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
title_full_unstemmed Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
title_short Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
title_sort immune checkpoint inhibitors in mcrpc - rationales, challenges and perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791446/
https://www.ncbi.nlm.nih.gov/pubmed/31646092
http://dx.doi.org/10.1080/2162402X.2019.1644109
work_keys_str_mv AT taghizadehh immunecheckpointinhibitorsinmcrpcrationaleschallengesandperspectives
AT marholdm immunecheckpointinhibitorsinmcrpcrationaleschallengesandperspectives
AT tomasiche immunecheckpointinhibitorsinmcrpcrationaleschallengesandperspectives
AT udovicas immunecheckpointinhibitorsinmcrpcrationaleschallengesandperspectives
AT merchanta immunecheckpointinhibitorsinmcrpcrationaleschallengesandperspectives
AT krainerm immunecheckpointinhibitorsinmcrpcrationaleschallengesandperspectives

Ejemplares similares